NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 16 June 2021

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Peter Selby (Vice Chair) Present for all items
3. Michael Chambers Present for items 5 to 7.1.3
4. Dr Prithwiraj Das Present for all items
5. Dr David Foreman Present for all items
6. Dr Natalie Hallas Present for all items
7. Dr Nigel Langford Present for all items
8. Dr Andrea Manca Present for all items
9. Iain McGowan Present for all items
10. Dr Mudasar Mushtaq Present for all items
11. Dr Richard Nicholas Present for all items
12. Ugochi Nwulu Present for all items
13. Stella O’Brien Present for all items
14. Professor Subhash Pokhrel Present for all items
15. Professor Andrew Renehan Present for items 1 to 4.2.2 & 6 to 7.1.3
16. Professor Matthew Stevenson Present for items 1 to 5.1.2
17. Professor Paul Tappenden Present for all items
18. Dr Derek Ward Present for items 1 to 6.2.2

NICE staff present

Meindert Boysen, Deputy Chief Executive and Director of CHTE Present for items 7 to 7.1.3

Helen Knight, Programme Director Present for items 7 to 7.1.3

Ross Dent, Associate Director Present for items 1 to 6.2.2

Linda Landells, Associate Director Present for items 7 to 7.1.3

Louise Jafferally, Project Manager Present for all items

Kate Moore, Project Manager Present for items 6 to 7.1.3

Caron Jones, Health Technology Assessment Adviser Present for items 1 to 4.2.2

Charlie Hewitt, Health Technology Assessment Adviser Present for items 5 to 5.2.2

Alex Filby, Health Technology Assessment Adviser Present for items 6 to 6.2.2

Zain Hussain, Health Technology Assessment Analyst Present for items 1 to 4.2.2

Catherine Parker, Health Technology Assessment Analyst Present for items 5 to 5.2.2

Elizabeth Bell, Health Technology Assessment Analyst Present for items 6 to 6.2.2

Alan Moore, Health Technology Assessment Analyst Present for items 7 to 7.1.3

Jacob Grant, Health Technology Analyst, DAP Present for items 1 to 4.2.2 & 6 to 6.2.2

Mohammed Towhasir, Coordinator, Topic Selection Present for items 5 to 5.1.3 & 6 to 6.1.3

Edgar Masanga, Business Analyst, RIA Present for all items

Olivia Havercroft, Senior Medical Editor Present for items 1 to 4.2.2

Sarah Bromley, Senior Medical Editor Present for items 5 to 5.2.2

Ria Skelton, Senior Medical Editor Present for items 6 to 6.2.2

Benjamin Pearce, Senior Medical Editor Present for items 7 to 7.1.3

Emily Eaton Turner, Technical Adviser, Commercial Risk Assessment Present for all items

Stevie Okoro, Technical Analyst, Commercial Risk Assessment, Present for items 6 to 7.1.3

Claire Hawksworth, Technical Analyst, Evidence Generation, Present for items 5 to 5.2.2

Mandy Tonkinson, Public Involvement Adviser, PIP Present for items 1 to 4.1.3 & 5 to 5.1.3

Sandra Robinson, Assistant Project Manager, Corporate Office, Present for items 1 to 4.1.3 & 6 to 6.1.3

Catherine Pank, Assistant Project Manager, COT Present for items 5 to 6.2.2

Rosalee Mason, Coordinator, Corporate Office Present for items 5 to 5.1.3

Mira Patel, Coordinator, COT Present for items 6 to 6.2.2

Gemma Smith, Coordinator, COT Present for all items

Celia Mayers, Administrator, TA Present for items 6 to 7.1.3

Sophie McHugh, Administrator, COT Present for items 5 to 5.2.2

Hollie Kemp, Apprentice, COT Present for items 1 to 4.2.2

Evidence review group representatives present

Graham Scotland, Aberdeen HTA Group Present for items 1 to 4.1.3

Miriam Brazzelli, Aberdeen HTA Group Present for items 1 to 4.1.3

Marrissa Martyn-St James, School of Health and Related Research (ScHARR)

Present for items 5 to 5.1.3

Marie Westwood, Kleijnen Systematic Reviews Ltd Present for items 6 to 6.1.3

Maiwenn Al, Kleijnen Systematic Reviews Ltd Present for items 6 to 6.1.3

Clinical & patient experts present

Rachel Annals, Patient expert nominated by HAE UK Present for items 1 to 4.1.3

Dr Tomaz Garcez, Consultant Immunologist, Clinical expert nominated by the British Society for Allergy and Clinical Immunology Present for items1 to 4.1.3

Laura Szutowicz, Patient expert nominated by HAE UK Present for items 1 to 4.1.

Dr Patrick Yong, Consultant Immunologist, Clinical expert nominated by HAE UK, The Royal College of Pathologists and UKPIN (UK Primary Immunodeficiency Network) Present for items 1 to 4.1.3

Professor Peter Clark, National Clinical Lead for cancer drugs, NHS England Present for items 5 to 6.2.2

Professor Claire Harrison, Clinical expert nominated by Celgene, a BMS Company Present for items 5 to 5.1.3

Professor Adam Mead, Professor of Haematology, Clinical expert nominated by MPN Voice Present for items 5 to 5.1.3

Mark Rutherford, Patient expert nominated by MPN Voice Present for items 5 to 5.1.3

Caroline Thomas, Patient expert nominated by MPN Voice Present for items 5 to 5.1.3

External observer present

Dr Charles Crawley, Consultant Haematologist & Chair Joint Drugs & Therapeutics Committee, Present for items 1 to 4.2.2

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 11 May 2021

### Appraisal of berotralstat for preventing acute attacks of hereditary angioedema (ID1624)

* 1. Part 1 – Open session
     1. The Chair Professor Stephen O’Brien welcomed the invited clinical and patient experts, external review group representatives, members of the public, external observer, and company representatives from BioCryst Pharmaceuticals.
     2. The chair asked all committee members, clinical and patient experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers had declared before the meeting that in 2020 he attended a Biocryst advisory board for this medicine. As a direct financial conflict, it was agreed Michael would not participate in the discussion of this appraisal and he did not attend the meeting.
* Nominated patient expert Rachel Annals declared financial interests as she has carried out some part time work for HAE UK. She also noted that HAE UK has received unrestricted financial grants from Biocryst (2018-2019), CSL Behring (2014-2020), Kalvista (2018), Pharming (2018) and Shire (2014 -2020)
* It was agreed that her declaration would not prevent Rachel from providing expert advice to the committee.
* Nominated clinical expert Dr Tomaz Garcez declared financial interests as he has received payments for advisory boards and speaking engagements at educational sessions for Takeda, Pharming, BioCryst, CSL Behring, Octapharma.
* It was agreed that his declarations would not prevent Dr Garcez from providing expert advice to the committee.
* Nominated patient expert Laura Szutowicz declared financial interests as she is the chief executive of the patient support and advocacy charity HAE UK and HAE UK has received unrestricted financial grants from BioCryst (2018-2019), CSL Behring (2014-2021), Kalvista (2018), Pharming (2018) and Shire (2014 -2020).
* It was agreed that her declarations would not prevent Laura from providing expert advice to the committee.
* Nominated clinical expert Dr Patrick Yong declared financial interests as he has received payments for advisory boards and speaking engagements for BioCryst, CSL Behring, Shire/Takeda and Pharming.
* It was agreed that his declarations would not prevent Dr Yong from providing expert advice to the committee.
* No further conflicts of interest were declared for the technology.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Iain McGowan, Professor Paul Tappenden and Ugochi Nwulu.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

### Appraisal of fedratinib for disease-related splenomegaly and symptoms in myelofibrosis (ID1501)

* 1. Part 1 – Open session
     1. The Chair Professor Stephen O’Brien welcomed the invited clinical and patient experts, the national clinical lead for cancer drugs, external review group representatives, members of the public and company representatives from Celgene.
     2. The chair asked all committee members, clinical and patient experts, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Richard Nicholas declared a financial interest as he has attended paid advisory boards with Roche and Novartis for treatment in an unrelated area (MS).
* It was agreed that his declaration would not prevent Dr Nicholas from participating in this section of the meeting.
* Committee Chair Professor Stephen O’Brien declared that, in his role as a consultant haematologist, he looks after patients with myelofibrosis but had no financial interests to declare.
* It was agreed that his declaration would not prevent Professor O’Brien from participating in this section of the meeting.
* Committee member Professor Matthew Stevenson declared a non-financial interest as he is employed by ScHARR he confirmed he has not been involved in the production or peer review of the ERG report.
* It was agreed that his declaration would not prevent Professor Stevenson from participating in this section of the meeting.
* Committee member Professor Paul Tappenden declared a non-financial interest as he is employed by ScHARR, he confirmed he has not been involved in the production or peer review of the ERG report.
* It was agreed that his declaration would not prevent Professor Tappenden from participating in this section of the meeting.
* Nominated clinical expert Professor Claire Harrison declared financial interests as she was chief investigator for the JAKARTA2 study and involved with JAKARTA1. She has also received payment for speaking and advisory boards. Her institute has received research grants from Celgene as well as other companies.
* It was agreed that her declarations would not prevent Professor Harrison from providing expert advice to the committee.
* Nominated clinical expert Professor Adam Mead declared financial interests as he has participated in advisory boards for Novartis, Celgene/Bristol-Myers Squibb (BMS) and Pfizer and received honoraria, research funding, travel, accommodations, and expenses from Novartis and Celgene/BMS. He also noted that MPN Voice received a grant from Celgene in 2019: £10,000 – support for National Patient Day and an application to Celgene for financial support has been granted, but funds not yet received (£10,000 – support for patient events)
* It was agreed that his declarations would not prevent Professor Mead from providing expert advice to the committee.
* No further conflicts of interest were declared for the technology.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Derek Ward, Dr Prithwiraj Das and Ugochi Nwulu.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

### Appraisal of pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations (ID3740)

* 1. Part 1 – Open session
     1. The Chair Professor Stephen O’Brien welcomed the external review group representatives, members of the public and company representatives from Incyte Biosciences UK.
     2. The chair asked all committee members, the national clinical lead for cancer drugs, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, external review group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (ID1647)

* 1. Part 2 – Closed session (Committee members and NICE representatives only).
     1. The chair Professor Stephen O’Brien asked all committee members and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Prithwiraj Das declared non-financial professional interests as he works at AstraZeneca UK as the Head of Market Access for Respiratory and Immunology therapies and Vaccines. He also noted that rosuvastatin is listed as one of the comparators but to his knowledge this is not currently promoted, and he has not been involved in work related to this appraisal.
* It was agreed that his declaration would not prevent Dr Das from participating in this section of the meeting.
* Committee member Dr Richard Nicholas declared a financial interest as he has attended paid advisory boards with Roche and Novartis for treatment in an unrelated area (MS).
* It was agreed that his declaration would not prevent Dr Nicholas from participating in this section of the meeting.
* No further conflicts of interest were declared for the technology.
  + 1. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus.
    2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 13 July 2021 and will start promptly at 9:30am.